EtoposideAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsTopoisomerase II InhibitorsCisplatinIfosfamideCarcinoma, Small CellDNA Topoisomerases, Type IIDrug Administration SchedulePodophyllotoxinDoxorubicinVincristineCyclophosphamideCarboplatinAmsacrineAdministration, OralAntineoplastic AgentsBleomycinLung NeoplasmsCombined Modality TherapyCytarabineTreatment OutcomeGerminomaInfusions, IntravenousTeniposideLeukopeniaRemission InductionTransplantation, AutologousNucleic Acid Synthesis InhibitorsApoptosisDrug EvaluationTopoisomerase InhibitorsDrug Resistance, NeoplasmMitoxantroneTesticular NeoplasmsDNA DamageNeoplasms, Germ Cell and EmbryonalCamptothecinHodgkin DiseaseTime FactorsHematologic DiseasesCarmustineNeutropeniaSurvival AnalysisDisease-Free SurvivalLymphoma, Non-HodgkinSalvage TherapyTumor Cells, CulturedTopotecanThrombocytopeniaSurvival RateDrug ResistanceTopoisomerase I InhibitorsPrednisonePaclitaxelRadiation DosageLethal Dose 50RazoxaneOrganophosphorus CompoundsNeoplasmsMelphalanCell SurvivalProcarbazineP-GlycoproteinVinblastineRadiotherapy DosageHalf-LifeDrug Resistance, MultipleDrug SynergismDose-Response Relationship, DrugDose FractionationGranulocyte Colony-Stimulating FactorMethotrexateDrug InteractionsCell Line, TumorDose-Response Relationship, RadiationDaunorubicinAlopeciaHematopoietic Stem Cell TransplantationRetroperitoneal NeoplasmsArea Under CurveBone Marrow DiseasesBiological AvailabilityInjections, IntravenousRadiometryDrug Screening Assays, AntitumorMesnaMetabolic Clearance RateHL-60 CellsAntibiotics, AntineoplasticRecurrenceCaspasesLevoleucovorinSmall Cell Lung CarcinomaLeukemiaNeuroblastomaEnzyme InhibitorsBone Marrow TransplantationDNA Topoisomerases, Type INeoplasm Recurrence, Local